Once-daily intravenous busulfan as myeloablative, reduced-toxicity conditioning regimen: results in young and adult patients with hematological malignant and nonmalignant diseases. Hematol Meeting Rep. 2009;2(6). doi:10.4081/hmr.v2i6.771